Diabetes Treatment Guidelines 2026

Diabetes Treatment Guidelines 2026: Is Metformin Still First-Line?

A practical, evidence-based guide to choosing therapy by A1C, cardiovascular disease, heart failure, kidney disease, obesity, liver disease, hypoglycemia risk and cost

UPDATED
17 October 2026

FOCUS
Type 2 diabetes in nonpregnant adults

EVIDENCE BASE
ADA Standards 2026 + ADA/EASD Oct 2026 consensus

THE 2026 ANSWER IN 20 SECONDS Metformin is still a highly effective, low-cost foundational drug for many people with type 2 diabetes, but it is no longer a mandatory universal first choice. In 2026, therapy begins with the person’s dominant clinical problem: ASCVD/high cardiovascular risk, heart failure, chronic kidney disease, obesity, metabolic liver disease, severe hyperglycemia, hypoglycemia risk, cost and treatment burden. SGLT2 inhibitors and/or GLP-1–based therapies may be used early—even from diagnosis and independent of current A1C or metformin use—when organ protection or weight reduction is a priority.

The central 2026 principle: choose treatment for the whole cardiometabolic phenotype, not for the glucose number alone.

The 10 take-home points that define diabetes care in 2026

Metformin remains important—but “metformin first for everyone” is outdated. For uncomplicated type 2 diabetes, metformin remains a sensible, effective and inexpensive option. When cardiovascular, kidney, heart-failure, weight or liver priorities dominate, another class may deserve equal or earlier priority.
Organ protection can be independent of A1C.
SGLT2 inhibitors and GLP-1 receptor agonist–based therapies are selected for cardiovascular and kidney outcomes even when glycemia is already near target.
Earlier use of modern therapies is now emphasized.
The October 2026 ADA/EASD consensus advocates earlier use—potentially from diagnosis—of SGLT2 inhibitors and/or GLP-1–based therapies when their organ-protective or weight benefits fit the patient.
Heart failure strongly favors an SGLT2 inhibitor.
This applies to both reduced and preserved ejection fraction. In obesity with symptomatic HFpEF, selected GLP-1 or dual GIP/GLP-1 therapies also have a role in symptoms and events.
CKD requires a layered strategy.
RAS blockade when indicated, an SGLT2 inhibitor from eGFR 20 mL/min/1.73 m² when appropriate, a GLP-1 receptor agonist for additional cardiovascular/kidney benefit, and finerenone for persistent albuminuric CKD in eligible patients.
Weight is a treatment target, not a cosmetic side issue.
A 5–7% loss improves glycemia and risk factors; sustained loss above 10% usually produces larger disease-modifying benefits and can allow remission in selected people.
GLP-1–based therapy is usually preferred before insulin when severe hyperglycemia is absent.
If insulin is needed, combining it with GLP-1–based therapy can improve glycemic efficacy and reduce weight gain and hypoglycemia burden.
Severe or catabolic hyperglycemia still means insulin.
Think insulin when symptoms are present, A1C is above 10%, glucose is at least 300 mg/dL, ketosis/catabolism is present, or type 1 diabetes is possible.
CGM has moved beyond type 1 diabetes.
Continuous glucose monitoring is recommended for people on insulin and can help selected people on noninsulin therapy, especially where hypoglycemia or pattern recognition matters.
Prevention of complications remains non-negotiable.
Blood pressure, lipids, smoking, kidney screening, eye care, neuropathy/foot surveillance, nutrition, activity and sleep often affect outcomes as much as the glucose-lowering drug itself.

Scope note. This pillar focuses on type 2 diabetes in nonpregnant adults. Type 1 diabetes, pregnancy, pediatrics, hyperglycemic emergencies and inpatient diabetes require dedicated protocols. Drug approvals and labels vary by country; local prescribing information and clinical judgment still apply.

On this page: The core concepts that help you manage better

Diagnosis and glycemic targets
Is metformin still first-line?
The 2026 treatment algorithm
Choosing therapy by cardiovascular, heart-failure, kidney, weight and liver phenotype
Drug-class comparison
When to start insulin
Lifestyle, weight loss and remission
CGM and diabetes technology
Blood pressure, lipids and antiplatelet therapy
Screening for kidney, eye, nerve and foot complications
Common clinical questions and exam pearls
Frequently asked questions
References

1. Diagnosis and glycemic targets: start with the basics

Diabetes treatment only makes sense after the diagnosis is secure and the target is individualized. In a person without unequivocal hyperglycemia, an abnormal diagnostic result should generally be confirmed with a second abnormal result. A1C can be misleading when red-cell turnover, hemoglobin variants, severe anemia, recent transfusion, pregnancy, or advanced kidney disease materially distort the assay; in those settings, plasma glucose criteria may be more reliable. [2]

Diagnostic thresholds for diabetes

Test	Diabetes threshold	Practical note
A1C	≥6.5% (48 mmol/mol)	Use a standardized laboratory method.
Fasting plasma glucose	≥126 mg/dL (7.0 mmol/L)	Fasting means no caloric intake for at least 8 hours.
2-hour plasma glucose after 75-g OGTT	≥200 mg/dL (11.1 mmol/L)	Useful when fasting glucose/A1C are discordant or suspicion remains high.
Random plasma glucose	≥200 mg/dL (11.1 mmol/L)	Diagnostic when classic hyperglycemic symptoms or a hyperglycemic crisis are present.

Targets for many nonpregnant adults

Metric	Typical 2026 target	Important nuance
A1C	<7%	Lower targets such as <6.5% may suit healthy people with low treatment risk; less stringent targets may suit frailty, major comorbidity or high hypoglycemia burden.
Premeal glucose	80–130 mg/dL	Individualize to treatment and hypoglycemia risk.
Peak postmeal glucose	<180 mg/dL	Especially useful when A1C remains high despite fasting/premeal control.
CGM time in range 70–180 mg/dL	>70%	For many adults; older or complex patients may need more permissive goals.
CGM time <70 mg/dL	<4%	For older adults, a target <1% is often used.
CGM time <54 mg/dL	<1%	Persistent exposure here should trigger treatment deintensification or adjustment.

Clinical pearl: A target is not a trophy number. It is a negotiated balance between prevention of microvascular disease, treatment burden, hypoglycemia, life expectancy, comorbidity and what the person can realistically sustain.

2. Is metformin still first-line in 2026?

Yes for many patients; no as a universal rule. Metformin remains effective, inexpensive, weight neutral or associated with modest weight loss, and has minimal hypoglycemia risk as monotherapy. It is still a common first medication when the main goal is glucose lowering and there is no dominant cardiovascular, kidney, heart-failure, liver or weight indication that should drive another choice. [5, 11]

The 2026 shift is that clinicians should not delay a treatment with proven organ benefit simply because metformin has not been tried first. In people with established or high cardiovascular risk, heart failure, CKD, obesity or other compelling comorbidity, SGLT2 inhibitors and/or GLP-1–based therapies may deserve early use, potentially from diagnosis, and their cardiorenal benefits are not dependent on metformin use. The October 2026 ADA/EASD consensus explicitly moves type 2 diabetes management beyond a “stepwise glucose-only” model toward earlier organ protection. [1, 5, 11]

When metformin is especially attractive—and when it is not enough

Metformin is especially attractive when…	Do not let metformin delay…
• Cost and broad availability are major considerations.	• An SGLT2 inhibitor in heart failure or eligible CKD.
• The main unmet goal is glycemic lowering without weight gain or hypoglycemia.	• A GLP-1 receptor agonist and/or SGLT2 inhibitor in established/high-risk ASCVD.
• There is no compelling ASCVD/HF/CKD/obesity/MASH reason to prioritize another class.	• A highly effective weight-lowering strategy when obesity is a primary treatment goal.
• The patient prefers an oral, familiar therapy and tolerates it well.	• Insulin in severe symptomatic or catabolic hyperglycemia.

Metformin safety points worth remembering

Metformin should not be used when eGFR is below 30 mL/min/1.73 m²; dose reduction and closer review should be considered as eGFR falls below 45 mL/min/1.73 m². [11]
Gastrointestinal intolerance often improves with slow titration, taking the drug with meals, or using an extended-release formulation.
Long-term therapy increases the risk of vitamin B12 deficiency. Periodic B12 assessment is appropriate, particularly with anemia or neuropathy; annual monitoring is reasonable after more than four years of therapy or when other B12 risk factors are present. [10]
If A1C reaches target on metformin, that usually means the treatment is working—not that metformin must be stopped. Deintensify only when the risk, burden or contraindication outweighs ongoing benefit.

3. The practical 2026 treatment algorithm

A useful way to teach the 2026 approach is to ask five questions in order. This avoids therapeutic inertia and prevents the common mistake of choosing a glucose-lowering drug without considering whether the heart, kidney, liver or body weight should drive the decision first.

Step 1 — Is there severe hyperglycemia or catabolism?
If there are marked symptoms, unexpected weight loss, ketosis, acute glycemic decompensation, A1C >10% or glucose ≥300 mg/dL, insulin should be strongly considered. If type 1 diabetes is possible, do not delay insulin while classification is being clarified.

Step 2 — Is there ASCVD, high cardiovascular risk, heart failure or CKD?
Use an SGLT2 inhibitor and/or GLP-1 receptor agonist with demonstrated outcome benefit according to the dominant phenotype—irrespective of A1C and irrespective of whether metformin is being used.

Step 3 — Is obesity or weight loss a major treatment goal?
Prioritize high-efficacy weight-lowering therapy. In 2026 guidance, semaglutide and tirzepatide are among the preferred pharmacologic options when clinically appropriate and accessible.

Step 4 — Is MASLD/MASH a major comorbidity?
Weight loss remains central. GLP-1–based therapy with evidence in MASH is favored; pioglitazone remains relevant in selected patients; tirzepatide has emerging/recognized potential. High-fibrosis-risk patients merit specialist co-management.

Step 5 — If no compelling comorbidity dominates, what best achieves the person’s glycemic goal?
Choose based on efficacy, hypoglycemia risk, weight effect, adverse effects, route, cost, access and preference. Metformin remains an excellent default in many such patients. If A1C is about 1.5–2.0 percentage points above the individual target, initial combination therapy is often needed.

4. Choose therapy by phenotype: heart, kidney, weight and liver first

Clinical phenotype	Preferred direction	Why it matters	Key caution
Established ASCVD or high ASCVD risk	GLP-1 RA and/or SGLT2 inhibitor with proven CV benefit	Reduces cardiovascular events beyond glucose lowering; combination may provide additive cardiorenal benefit in selected patients.	Use agents with demonstrated outcome benefit; do not generalize a class effect to every molecule.
Heart failure: HFrEF or HFpEF	SGLT2 inhibitor	Reduces worsening HF/hospitalization and CV death across ejection-fraction phenotypes.	Assess volume status; educate about genital infections and ketoacidosis risk.
Obesity + symptomatic HFpEF	SGLT2 inhibitor plus consideration of GLP-1 or dual GIP/GLP-1 therapy with demonstrated HFpEF benefit	Addresses both HF outcomes/symptoms and weight.	Choose evidence-based agents and titrate to tolerability.
CKD, eGFR ≥20 and/or albuminuria	SGLT2 inhibitor; add/consider GLP-1 RA; RAS blockade and finerenone when indicated	Slows kidney disease and reduces cardiovascular events.	Glycemic effect of SGLT2 inhibitors falls as eGFR declines, but organ benefit persists.
Persistent albuminuric CKD on ACEi/ARB	Finerenone if eligible	Further reduces CKD progression and CV risk.	Monitor potassium and kidney function; avoid inappropriate combination with another MRA.
Overweight/obesity	GLP-1 RA or dual GIP/GLP-1 RA with high weight-loss efficacy; consider metabolic surgery when appropriate	Weight management is a primary treatment target; larger sustained loss may modify disease course and permit remission.	GI tolerability, gallbladder disease, lean-mass preservation, cost and long-term continuation matter.
MASLD/MASH	GLP-1 RA with MASH benefit; consider tirzepatide or pioglitazone in selected patients	Can improve steatohepatitis while addressing weight and glycemia.	Fibrosis staging matters; advanced disease needs hepatology input.
High hypoglycemia risk	Favor metformin, SGLT2, GLP-1–based therapy, DPP-4 inhibitor, or other low-hypoglycemia options	Avoids preventable falls, arrhythmia, cognitive burden and treatment fear.	Reassess sulfonylurea/insulin doses when adding a potent low-hypoglycemia agent.
Major cost/access constraints	Metformin; selected sulfonylurea, TZD, or human insulin when needed	Affordability determines adherence and therefore real-world effectiveness.	Lower cost must be balanced against hypoglycemia, weight gain, edema and organ-outcome differences.

ASCVD: glucose lowering is no longer the only reason to choose a drug

For established ASCVD, multiple ASCVD risk factors, or CKD, a GLP-1 receptor agonist and/or an SGLT2 inhibitor with demonstrated cardiovascular benefit should be part of the risk-reduction strategy even if A1C is already at goal. Combination therapy may be considered in selected high-risk patients for complementary cardiovascular and kidney benefit. [7]

Heart failure: SGLT2 inhibition is a disease-modifying choice

Layer	2026 practical approach
Measure the disease	Check eGFR and spot urine albumin-to-creatinine ratio (UACR) at least annually in all type 2 diabetes.
Control intraglomerular pressure	Use ACE inhibitor or ARB when hypertension and albuminuria/CAD indicate it; titrate to a tolerated evidence-based dose.
Add SGLT2 inhibition	Initiate an SGLT2 inhibitor with proven benefit when eGFR is ≥20 mL/min/1.73 m² and continue as appropriate toward kidney failure.
Add GLP-1–based therapy when useful	Use for additional glycemic management and cardiovascular/kidney risk reduction, particularly when obesity or ASCVD coexists.
Address residual albuminuric risk	Use finerenone in eligible type 2 diabetes with albuminuric CKD despite RAS blockade, with potassium/eGFR monitoring.
Selected early combination	ADA 2026 allows consideration of simultaneous SGLT2 inhibitor + finerenone in adults with UACR ≥100 mg/g and eGFR 30–90 on RAS inhibition, based on safety and albuminuria reduction data.

Obesity: treatment success is no longer defined by A1C alone

The 2026 Standards treat weight management as a primary therapeutic goal alongside glycemic control. A sustained 5–7% loss improves glycemia and cardiovascular risk factors; sustained loss above 10% usually produces larger benefits and can have disease-modifying effects, including possible remission of type 2 diabetes. Semaglutide or tirzepatide are preferred obesity pharmacotherapy options in many people with diabetes and overweight/obesity when appropriate. [4]

MASLD/MASH: the liver now influences diabetes drug choice

In type 2 diabetes with MASLD plus overweight/obesity, weight loss is foundational. For biopsy-proven MASH or high fibrosis risk, GLP-1 receptor agonist therapy with demonstrated MASH benefit is preferred for glycemic management; pioglitazone remains a reasonable option in selected patients, and dual GIP/GLP-1 therapy can be considered where appropriate. Advanced fibrosis should trigger specialist evaluation rather than “treating the ALT.” [12]

5. Diabetes drug classes in 2026: what each class is best at

Class	Glucose efficacy	Weight	Hypoglycemia alone	Best use / outcome advantage	Key limitation
Metformin	High	Neutral / modest loss	Low	Low cost; effective foundational therapy	GI effects; B12 deficiency; avoid eGFR <30
SGLT2 inhibitors	Intermediate–high; less glycemic effect at low eGFR	Modest loss	Low	HF and CKD protection; CV benefit with selected agents	Genital mycotic infection, volume depletion, euglycemic DKA; perioperative/fasting precautions
GLP-1 receptor agonists	High to very high	Loss, often substantial	Low	ASCVD reduction with selected agents; weight; kidney benefit; some HFpEF/MASH benefit	GI effects, gallbladder disease; gastroparesis concern; agent-specific precautions
Dual GIP/GLP-1 agonist (tirzepatide)	Very high	Very high loss	Low	Powerful A1C and weight effect; obesity/HFpEF and liver relevance	GI effects; access/cost; long-term therapy usually needed
DPP-4 inhibitors	Intermediate	Neutral	Low	Simple oral option; linagliptin needs no renal dose adjustment	Less potent; no meaningful weight loss; do not combine with GLP-1–based therapy
Sulfonylureas	High	Gain	Yes	Low cost, rapid glucose lowering	Hypoglycemia and weight gain; no organ-protection advantage
TZD (pioglitazone)	High	Gain / edema	Low	Insulin sensitization; useful in selected MASH patients	Edema, HF risk, fractures, weight gain
Insulin	Very high	Gain	Yes	Essential for type 1; severe/catabolic hyperglycemia; unlimited glucose-lowering potential	Hypoglycemia, weight gain, injections and monitoring burden

Do not combine a DPP-4 inhibitor with a GLP-1 receptor agonist or dual GIP/GLP-1 agonist. The 2026 Standards specifically advise against this because it does not add meaningful glucose lowering. [5]

6. When to start insulin—and when not to rush to it

Insulin is not a “failure” of oral therapy. It is the correct treatment when physiology demands it. Conversely, in adults with type 2 diabetes who do not have severe hyperglycemia or a hyperglycemic crisis, GLP-1–based therapy is preferred to insulin for initial or add-on glucose lowering. [5]

Start or strongly consider insulin when

A1C is >10% (86 mmol/mol) or blood glucose is ≥300 mg/dL (16.7 mmol/L), especially with symptoms.
Polyuria, polydipsia, dehydration, ketosis or unexpected weight loss suggests catabolism.
Type 1 diabetes is suspected or insulin deficiency is likely.
There is acute glycemic decompensation or a hyperglycemic crisis.
Noninsulin therapy cannot achieve individualized goals despite an optimized, adherent regimen.

A practical basal-insulin starting point

For many adults with type 2 diabetes, basal insulin can begin at approximately 0.1–0.2 units/kg/day and be titrated to fasting glucose while avoiding hypoglycemia. If fasting glucose reaches target but A1C remains high, do not keep escalating basal insulin indefinitely (“over-basalization”); address postprandial hyperglycemia with GLP-1–based therapy if not already used and/or introduce prandial insulin when needed. [5, 11]

Insulin safety rule: When a potent glucose-lowering therapy is added, reassess insulin and sulfonylurea doses. The goal is not to “stack” medications until hypoglycemia occurs; it is to preserve benefit while reducing unnecessary treatment burden.

7. Lifestyle, weight loss and remission: the 2026 “whole day” prescription

The October 2026 ADA/EASD consensus reframes lifestyle as a 24-hour treatment plan rather than a vague instruction to “diet and exercise.” Healthy eating, movement, resistance training, sleep, smoking/substance avoidance, psychological support and weight management are core therapy—not optional add-ons. [1, 11]

The five S’s of physical behavior

S	What it means in practice
Standing	Break up prolonged sitting, especially after meals.
Stepping	Increase daily movement progressively from baseline; walking after meals is simple and effective.
Sweating	Work toward ≥150 minutes/week of moderate-to-vigorous activity or an appropriate vigorous/interval equivalent, spread across the week.
Strengthening	Train major muscle groups on 2–3 days/week; preserving lean mass is especially important during major weight loss.
Sleeping	Aim for regular, restorative sleep; poor quantity, quality and timing worsen cardiometabolic health.

How much weight loss should be targeted?

5–7%: meaningful improvement in glycemia and intermediate cardiovascular risk factors.
>10% sustained: usually larger metabolic benefits, greater disease modification and possible type 2 diabetes remission in selected individuals.
~10% or greater through intensive lifestyle therapy may be deliberately targeted when remission is realistic and safe.
Metabolic surgery is the most powerful durable weight-loss intervention for appropriately selected patients and may produce diabetes remission and cardiovascular benefit.

Nutrition: there is no single “diabetes diet”

Medical nutrition therapy should identify a healthy dietary pattern that is culturally acceptable, affordable and sustainable. For people with established ASCVD, a Mediterranean dietary pattern is preferentially considered when feasible. Highly processed foods, excess refined carbohydrate, saturated/trans fat and sugar-sweetened beverages should be reduced; fiber-rich whole foods, legumes, vegetables, nuts, seeds and appropriate protein sources should be emphasized. Specific dietary supplements are not recommended as glucose-lowering therapy. [11]

8. CGM and diabetes technology: not just for type 1 diabetes anymore

The 2026 Standards recommend CGM at diabetes onset and thereafter for people using insulin, for people using noninsulin therapies that can cause hypoglycemia, and in other situations where CGM meaningfully improves management. Automated insulin delivery can be offered to adults with type 1 or type 2 diabetes on insulin according to needs, preferences, training and access. [3]

How to interpret CGM quickly

Time in range (70–180 mg/dL) >70% is a useful goal for many adults.
Time below 70 mg/dL should be <4%, and time below 54 mg/dL <1%.
Look at patterns, not isolated readings: overnight trends, post-meal excursions, variability and recurrent lows often reveal more than a single fasting value.
If CGM shows frequent hypoglycemia, deintensification may be more important than chasing a lower A1C.

9. Blood pressure, lipids and antiplatelet therapy: the outcomes layer

A modern diabetes plan is incomplete if the clinician focuses on A1C while leaving blood pressure and lipids untreated. For many people, the cardiovascular benefit of getting these right rivals or exceeds that of intensifying glucose therapy.

Blood pressure

For diabetes with hypertension, individualize the goal. If safely attainable, the 2026 ADA on-treatment target is <130/80 mmHg.
In people at high cardiovascular or kidney risk, a systolic target <120 mmHg should be encouraged when it can be reached safely.
ACE inhibitors or ARBs are especially important with albuminuria or coronary artery disease; do not combine ACE inhibitor + ARB.

Lipids

Most adults aged 40–75 years with diabetes should receive at least moderate-intensity statin therapy. In those at higher cardiovascular risk, high-intensity statin therapy is recommended with a goal of at least 50% LDL reduction and LDL <70 mg/dL. In established ASCVD, the LDL goal is <55 mg/dL, adding ezetimibe or a PCSK9-targeted therapy when needed. [7]

Aspirin

Aspirin 75–162 mg/day is standard secondary prevention for diabetes with established ASCVD unless contraindicated. For primary prevention, aspirin is not routine; it may be considered only in selected people with increased cardiovascular risk and low bleeding risk after shared decision-making. In older adults—especially above 70—the bleeding trade-off generally becomes less favorable. [7]

10. The complication-screening checklist every diabetes visit should feed into

Domain	At diagnosis / baseline	Ongoing frequency	High-yield point
A1C	Obtain baseline	About every 3 months when not at goal or therapy changes; about every 6 months when stable	Interpret with CGM and conditions that alter red-cell turnover.
Kidney	eGFR + spot UACR in all type 2 diabetes	At least annually; 1–4 times/year once CKD is present depending on stage	Albuminuria can rise before eGFR falls.
Eyes	Dilated comprehensive exam at type 2 diabetes diagnosis	Usually annually; every 1–2 years may be considered after normal exams and good control	Accelerated glucose improvement can transiently worsen retinopathy in susceptible patients; screen and monitor appropriately.
Neuropathy	Assess at type 2 diabetes diagnosis	At least annually	Check symptoms, pinprick/temperature, vibration and protective sensation.
Feet	Comprehensive foot exam	At least annually; every visit if sensory loss, prior ulcer or amputation	Inspect skin, deformity, pulses and 10-g monofilament/protective sensation.
Lipids	At diagnosis / initial evaluation	At least annually when clinically indicated; recheck 4–12 weeks after starting/changing lipid therapy	Treat risk, not just the laboratory number.
Vitamin B12 on metformin	Baseline when clinically indicated	Periodic; annual after >4 years or other B12 risk factors is reasonable	Think B12 when anemia or neuropathy appears.
Weight / BMI	At diagnosis	At least annually; every ~3 months during active weight management	Waist/adiposity measures can add risk information where feasible.

11. High-yield clinical questions and exam pearls

If A1C is 7% on metformin, should metformin be stopped?

Usually no. Reaching the goal generally means therapy is effective. Continue unless adverse effects, contraindications, excess burden or a deliberate deintensification strategy argues otherwise.

Best diabetes class in heart failure?

An SGLT2 inhibitor with demonstrated heart-failure benefit. The recommendation applies across reduced and preserved EF.

Best diabetes class in CKD?

For organ protection, an SGLT2 inhibitor is foundational when eGFR is ≥20 and appropriate; GLP-1 RA and finerenone are layered according to residual risk, albuminuria, glycemic/weight needs and eligibility.

What if eGFR is <30?

Metformin should not be used below eGFR 30. A GLP-1 receptor agonist is preferred for glycemic management in advanced CKD because of low hypoglycemia risk and cardiovascular benefit; SGLT2 organ-protective therapy may often be continued toward kidney failure if already indicated.

When do we go straight to insulin?

Severe symptomatic hyperglycemia, catabolism/ketosis, A1C >10%, glucose ≥300 mg/dL, acute decompensation, or possible type 1 diabetes.

Can DPP-4 inhibitors be combined with GLP-1 drugs?

No. The 2026 Standards advise against this because there is no meaningful added glucose lowering.

Does an SGLT2 inhibitor require a high A1C to justify use?

No. In HF, CKD and selected cardiovascular-risk settings, the indication is organ protection and is independent of A1C.

Which therapies are strongest for weight loss?

GLP-1–based therapy is central; semaglutide and tirzepatide are among the preferred high-efficacy options when clinically suitable.

Why check B12 in metformin users?

Long-term metformin can lower B12, which can cause or worsen neuropathy and anemia—exactly the complications that may otherwise be misattributed to diabetes.

12. Frequently asked questions

What is the biggest change in diabetes treatment guidelines in 2026?

The biggest conceptual change is not one new drug—it is earlier, phenotype-driven treatment. Cardiovascular, kidney, heart-failure, weight and liver outcomes now influence the initial plan instead of waiting for sequential “failure” of older glucose-lowering drugs.

Is metformin outdated?

No. Metformin remains one of the most useful diabetes medicines because it is effective, low-cost, familiar and has little hypoglycemia risk. What is outdated is treating it as a compulsory gatekeeper before using therapies that a patient already needs for organ protection or weight management.

Should everyone with type 2 diabetes receive a GLP-1 drug?

No. The decision depends on comorbidity, weight goals, contraindications, tolerability, access, cost and preference. These medicines are powerful, but a good guideline is a decision framework—not a mandate to use the same drug in everyone.

Should everyone with diabetes receive an SGLT2 inhibitor?

No. The strongest reasons are heart failure, CKD and selected cardiovascular-risk settings. eGFR, volume status, genital-infection risk, ketoacidosis risk, planned surgery/fasting and cost must be considered.

Can type 2 diabetes go into remission?

Yes, particularly early in the disease course after substantial sustained weight loss. Remission does not mean the future risk is erased; ongoing surveillance for recurrence and complications remains appropriate.

How often should A1C be checked?

Common practice is approximately every 3 months when therapy is changing or the target is not met, and about every 6 months when glycemia is stable and at goal. CGM can provide more immediate information between laboratory measurements.

What is a good A1C target for an older adult?

There is no single number. Healthy older adults may use targets similar to younger adults, while frailty, cognitive impairment, severe comorbidity, limited life expectancy or high hypoglycemia risk justify less stringent goals.

What should be treated first: glucose, blood pressure or cholesterol?

They should be treated together according to risk. In a person with diabetes and high cardiovascular risk, controlling blood pressure and LDL and using an organ-protective glucose-lowering drug may prevent more events than focusing narrowly on another small fall in A1C.

Important use note. This page is an educational synthesis of current guidance, not a substitute for individualized medical care. Prescribing must account for diagnosis, eGFR, liver status, pregnancy potential, current medications, adverse-effect risks, local product labels, affordability and patient preference.

13. References and primary guideline sources

Davies MJ, Aroda VR, Bajaj M, et al. Management of Type 2 Diabetes, 2026. A Consensus Report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. Published 2 October 2026. doi:10.2337/dci26-0141.
American Diabetes Association Professional Practice Committee for Diabetes. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-S002.
American Diabetes Association Professional Practice Committee for Diabetes. 7. Diabetes Technology: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-S007.
American Diabetes Association Professional Practice Committee for Diabetes. 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-S008.
American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-S009.
American Diabetes Association Professional Practice Committee for Diabetes. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-S006.
American Diabetes Association Professional Practice Committee for Diabetes. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-S010.
American Diabetes Association Professional Practice Committee for Diabetes. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-S011.
American Diabetes Association Professional Practice Committee for Diabetes. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-S012.
American Diabetes Association Professional Practice Committee for Diabetes. 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-S003.
American Diabetes Association Professional Practice Committee for Diabetes. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-S005.
American Diabetes Association Professional Practice Committee for Diabetes. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-S004.
American Diabetes Association Professional Practice Committee for Diabetes. Summary of Revisions: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S6–S12. doi:10.2337/dc26-SREV.